



## OPEN ACCESS

EDITED AND REVIEWED BY  
Zhangjun Cheng,  
Southeast University, China

## \*CORRESPONDENCE

Maolin Yan  
✉ yanmaolin74@163.com  
Weijia Liao  
✉ liaoweijia288@163.com

†These authors share first authorship

## SPECIALTY SECTION

This article was submitted to  
Cancer Immunity  
and Immunotherapy,  
a section of the journal  
Frontiers in Immunology

RECEIVED 16 March 2023  
ACCEPTED 27 March 2023  
PUBLISHED 11 April 2023

## CITATION

Li S, Wu J, Wu J, Fu Y, Zeng Z, Li Y, Li H,  
Liao W and Yan M (2023) Corrigendum:  
Prediction of early treatment response to  
the combination therapy of TACE plus  
lenvatinib and anti-PD-1 antibody  
immunotherapy for unresectable  
hepatocellular carcinoma: Multicenter  
retrospective study.  
*Front. Immunol.* 14:1187423.  
doi: 10.3389/fimmu.2023.1187423

## COPYRIGHT

© 2023 Li, Wu, Wu, Fu, Zeng, Li, Li, Liao and  
Yan. This is an open-access article  
distributed under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#). The  
use, distribution or reproduction in other  
forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in  
this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Corrigendum: Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study

Shuqun Li<sup>1,2†</sup>, Junyi Wu<sup>1,3†</sup>, Jiayi Wu<sup>1,3†</sup>, Yangkai Fu<sup>1</sup>,  
Zhenxin Zeng<sup>1</sup>, Yinan Li<sup>1</sup>, Han Li<sup>1</sup>, Weijia Liao<sup>2\*</sup>  
and Maolin Yan<sup>1,3\*</sup>

<sup>1</sup>Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China, <sup>2</sup>Department of Hepatobiliary Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China, <sup>3</sup>Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, Fujian, China

## KEYWORDS

unresectable hepatocellular carcinoma, TACE, lenvatinib, anti-PD-1 antibody, immunotherapy, nomogram

## A Corrigendum on

**Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study.**

By Li S, Wu J, Wu J, Fu Y, Zeng Z, Li Y, Li H, Liao W and Yan M (2023) *Front. Immunol.* 14:1109771. doi: 10.3389/fimmu.2023.1109771

In the published article, there was an error in [Table 2](#) as published. “Abnormal pain” should be “Abdominal pain”. The corrected [Table 2](#) and its caption “Treatment-related adverse events” appear below.

TABLE 2 Treatment-related adverse events.

Adverse Events	Any grade n(%)	Grade 1-2 n(%)	Grade 3 n(%)	Grade 4 n(%)
Total	142 (84.0)	103 (60.9)	32 (18.9)	7 (4.1)
Fatigue	40 (23.7)	34 (20.1)	6 (3.6)	-
Decreased appetite	39 (23.1)	30 (17.8)	9 (5.3)	-
Fever	52 (30.8)	50 (29.6)	2 (1.2)	-
Nausea	30 (17.8)	24 (14.2)	6 (3.6)	-
Vomiting	18 (10.7)	15 (8.9)	3 (1.8)	-
Abdominal pain	20 (11.8)	18 (10.7)	2 (1.1)	-
Hand-foot syndrome	24 (14.2)	19 (11.2)	4 (2.4)	1 (0.6)
Diarrhea	21 (12.4)	21 (12.4)	-	-
Hypertension	46 (27.2)	36 (21.3)	10 (5.9)	-
Proteinuria	18 (10.7)	12 (7.1)	5 (2.9)	1 (0.6)
Skin rash	19 (11.2)	13 (7.7)	4 (2.4)	2 (1.1)
Thrombocytopenia	24 (14.2)	24 (14.2)	-	-
Hypothyroidism	28 (16.6)	22 (13.0)	6 (3.6)	-
Abnormal liver function	105 (62.3)	86 (50.9)	16 (9.5)	3 (1.9)

In the published article, there was an error. The external validation cohort patients should be 67.

A correction has been made to **Materials and methods**, *Patients and study design*, Paragraph 1. This sentence previously stated:

“The external validation cohort (n = 68) included patients from Zhangzhou Municipal Hospital of Fujian Province, Fujian Medical University Union Hospital, and the First Affiliated Hospital of Xiamen University.”

The corrected sentence appears below:

“The external validation cohort (n = 67) included patients from Zhangzhou Municipal Hospital of Fujian Province, Fujian Medical University Union Hospital, and the First Affiliated Hospital of Xiamen University”

In the published article, there was an error. The ORR should be 60.9% and C-index in test cohort should be 0.800.

A correction has been made to **Abstract**, *Results*, Paragraph 1. This sentence previously stated:

“The ORR was 60.7% and the risk of early ORR was independently predicted by AFP, portal vein tumor thrombus (PVTT), tumor number, and size in both the training (C-index = 0.853) and test (C-index = 0.731) cohorts.”

The corrected sentence appears below:

“The ORR was 60.9% and the risk of early ORR was independently predicted by AFP, portal vein tumor thrombus (PVTT), tumor number, and size in both the training (C-index = 0.853) and test (C-index = 0.800) cohorts.”

In the published article, there was an error. The ORR should be 60.9%.

A correction has been made to **Results**, *3.1 Baseline features*, Paragraph 1. This sentence previously stated:

“The 3 months ORR of the entire cohort was 60.7%, comprising 147 males and 22 females, respectively.”

The corrected sentence appears below:

“The 3 months ORR of the entire cohort was 60.9%, comprising 147 males and 22 females, respectively.”

In the published article, there was an error. The ORR should be 60.9%.

A correction has been made to **Discussion**, Paragraph 1. This sentence previously stated:

“The early ORR in all u-HCC cohorts was 60.7%.”

The corrected sentence appears below:

“The early ORR in all u-HCC cohorts was 60.9%.”

In the published article, there was an error. The C-index in test cohort should be 0.800.

A correction has been made to **Discussion**, Paragraph 2. This sentence previously stated:

“An external cohort also calibrated the nomogram, with a high concordance index of 0.731.”

The corrected sentence appears below:

“An external cohort also calibrated the nomogram, with a high concordance index of 0.800.”


In the published article, there was an error. The C-index in test cohort should be 0.800.

A correction has been made to **Results**, *3.4 Model performance and validation*, Paragraph 1. This sentence previously stated:

“The C-index was 73.13% (95% CI, 63.52%–87.83%, **Figure 3**)”

The corrected sentence appears below:

“The C-index was 80.00% (95% CI, 63.52%–87.83%, **Figure 3**)”



The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated